Business
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) (\"Adhera\" or the \"Company\"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Marketplace (the “OTCQB”). Adhera will commence trading on the OTCQB at the market open on January 20, 2022 under the ticker “ATRX.” The Company believes that the uplist will create greater visibility to retail and institutional investors, as well as further enhance trading liquidity. The OTCQB is operated by OTC Markets Group Inc. and recognized by the U.S. Securities and Exchange Commission as a market providing public information for analysis and value of securities. The OTCQB is designed for developing U.S. and international companies, subject to ongoing listing requirements that include remaining current in financial reporting, undergoing an annual verification and management certification process, meeting a minimum bid price, and other specific financial conditions. “Moving to the OTCQB is the result of our commitment to compliance, quality controls, and complete transparency to our current shareholders and those that will become shareholders of ATRX in the future,” commented Andrew Kucharchuk, Chief Executive Officer of Adhera Therapeutics. “It is a significant milestone and a logical progression for the Company as part of our goal to make 2022 a transformational year for Adhera. In that pursuit, we are actively engaged with companies, funds, and individuals that share our vision to advance our drug pipeline addressing unmet medical needs into Phase 2 clinical trials, and graduate Adhera to a listing on a national exchange. We look forward to providing our shareholders regular updates on our progress in the coming weeks and months.” About Adhera Therapeutics Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. The Company has licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-10...